TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
Last trade$0.7766
Day change+$0.015 (+1.97%)
Day range$0.757 – $0.829
Volume51,602
Market cap$34M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$34.34M
Price / earnings
—
Price / book
-1.4×
Price / sales
0.44×
EV / sales
0.87×
EV / EBITDA
-2.08×
Profitability
Earnings per share
-$0.93
Return on assets
-84.61%
Return on equity
170.4%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-2.29×
Current ratio
0.61×
Quick ratio
0.45×
Cash ratio
0.31×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$34.39M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TELA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$18.96M
$19.29M
$19.06M
$20.87M
$20.69M
$20.2M
$18.52M
$17.65M
Cost of revenue
$8.64M
$5.35M
$6.54M
$7.11M
$6.88M
$6.09M
$6.01M
$6.43M
Gross profit
$10.32M
$13.94M
$12.52M
$13.76M
$13.81M
$14.11M
$12.51M
$11.22M
Selling, general and administrative
$16.01M
$20.5M
$20.7M
$18.27M
$19.01M
$20.98M
$20.44M
$17.55M
Research and development
$1.6M
$2.72M
$2.34M
$2.13M
$2.35M
$2.2M
$2.54M
$2.03M
Total operating expenses
$17.61M
$23.23M
$23.05M
$20.4M
$21.36M
$23.19M
$22.98M
$19.58M
Operating income
-$7.29M
-$9.28M
-$10.53M
-$6.65M
-$7.55M
-$9.08M
-$10.47M
-$8.35M
Interest expense
-$2.1M
-$2.08M
-$2.05M
-$1.64M
-$1.2M
-$1.19M
-$1.22M
-$1.28M
Income before taxes
-$9.2M
-$11.2M
-$12.21M
-$8.9M
-$8.6M
-$9.89M
-$11.21M
-$9.35M
Income taxes
$103K
$60K
$60K
$145K
$0
$33K
$52K
-$144K
Net income
-$9.3M
-$11.26M
-$12.27M
-$9.04M
-$8.6M
-$9.92M
-$11.26M
-$9.21M
Net income attributable to common shareholders
-$9.3M
-$11.26M
-$12.27M
-$9.04M
-$8.6M
-$9.92M
-$11.26M
-$9.21M
EBITDA
-$7.02M
-$9.02M
-$10.26M
-$6.42M
-$7.31M
-$8.81M
-$10.21M
-$8.09M
Basic earnings per share
-$0.16
-$0.20
-$0.21
-$0.17
-$0.19
-$0.22
-$0.25
-$0.23
Diluted earnings per share
-$0.16
-$0.20
-$0.21
-$0.17
-$0.19
-$0.22
-$0.25
-$0.23
Recent news
Company coverage with links to the original publishers.
TELA Bio exceeded EPS expectations with a loss of $0.13 per share versus consensus estimate of $0.19, representing a 31.58% earnings surprise. However, revenues declined to $18.96 million from $20.69 million year-over-year. The stock has underperformed the market by 26.7% year-to-date and carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
TELA Bio reported Q3 2026 revenue of $19.0 million with a 21% sequential reduction in operating loss and 55% improvement in adjusted EBITDA loss. The company implemented a $17.0 million cost reduction initiative to extend cash runway into 2028, regained Nasdaq compliance, and received 510(k) clearance for a new product. Despite revenue declining 8% year-over-year, the company demonstrated improved operational efficiency and continued international growth.
Oculis Holding AG (OCS) reported a quarterly loss of $0.37 per share, beating consensus estimates of $0.49 loss by 24.49%, but revenues of $0.01 million significantly missed expectations by 96.93%. The stock has declined 61.4% year-to-date, underperforming the S&P 500's 10.2% gain. Despite the miss, the company maintains a Zacks Rank #2 (Buy) rating based on favorable estimate revision trends.
TELA Bio announced FDA 510(k) clearance for its Liora Monofilament Scaffold, a fully resorbable surgical mesh device for soft tissue reinforcement. Liora is the first fully resorbable synthetic product in the company's portfolio to be designed and produced in-house at its ISO 8 certified cleanroom in Malvern, PA, expanding TELA Bio's soft tissue reconstruction market footprint.
TELA Bio, Inc. announced that its Compensation Committee approved inducement grants of restricted stock units covering 8,550 shares to three newly-hired employees with a grant date of February 18, 2026. The RSUs will vest in equal annual installments over four years, subject to continued service.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.